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Patterns of drug use among type 2 diabetic 
patients with comorbidities attending  
a tertiary centre in lagos, nigeria
AbSTRACT 
background. Diabetes care involves the use of drugs to 
control hyperglycaemia and the treatment of comor-
bid disorders to prevent cardiovascular morbidity and 
other complications. This study investigated patterns 
of comorbidities and drug use among diabetic patients 
at a tertiary centre in lagos, nigeria.
Methods. This was a cross-sectional study carried out 
among 216 patients with type 2 DM attending the 
Diabetes Clinic of a tertiary centre. Data was captured 
by using a questionnaire that documented biodata, 
number of comorbidities, number and combination 
of drugs for each participant and analysed using SPSS 
version 18. 
Results. Comorbidities were present among 215 out of 
216 (99.54%) participants and hypertension and dys-
lipidaemia were the most common comorbid disorders. 
The number of pills consumed per patient ranged from 
1 to10 with a mean of 4.78 ± 1.73 and 57.4% were on 
5 pills or more. A fixed-dose combination was used in 
37 (17.1%) of the patients. The majority of the patients 
were on metformin as monotherapy or in combina-
tion therapy. Antihypertensive most prescribed were 
renin-angiotensin system (RAS) blockers which were 
prescribed in 73% of participants. Antiplatelet drugs 
were used for both primary and secondary preven-
tion of CVDs. Statin was used in less than 50% of the 
population. Double RAS blockade was also observed 
in 6% of participants.
Conclusions. Comorbidities were common in the 
diabetic population. Pill load was high but appropri-
ate in most patients. Statin uptake was suboptimal 
while there was increased uptake of antiplatelet 
drugs among participants. (Clin Diabetol 2021; 10; 4: 
342–348) 
Key words: diabetes mellitus, comorbidities, 
antidiabetic drugs, type 2 DM, antihypertensive 
drugs
Introduction 
Type 2 Diabetes mellitus (T2DM) is one of the 
most common cardiovascular risk factors and is as-
sociated with high morbidity and mortality globally. 
It is a chronic disease characterized by relative or/and 
absolute insulin deficiency and insulin insensitivity 
which results in deficient metabolism of carbohydrate, 
protein, and lipids [1]. International Diabetes Federa-
tion (IDF) 2019 reported Diabetes prevalence in Nigeria 
as 3%, but this is probably underestimated because 
a systematic review by Uloko and colleagues published 
in 2018 found the prevalence of DM in Nigeria to be 
5.77% [2, 3].
The complications arising from diabetes mellitus 
(DM) are major contributors to increased hospitaliza-
tion and mortality. Complications from DM include 
atherosclerotic cardiovascular diseases such as coronary 
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heart disease, cerebrovascular disease, or peripheral 
arterial disease (PAD) presumed to be of atheroscle-
rotic origin and microvascular complications such as 
chronic kidney disease, retinopathy, and neuropathy 
[4]. Appropriate management of DM helps to prevent 
these complications.
The management of DM addresses glycaemic con-
trol and the prevention and management of complica-
tions. It also involves the treatment of comorbid cardio-
vascular risk factors like hypertension, dyslipidaemia, 
obesity [4, 5]. Consequently, patients with DM often 
require a relatively high number of drugs to achieve 
therapeutic goals.
The high pill load among this population calls for 
caution because of the increased risk of drug-drug 
interactions and drug-disease interaction which may 
lead to reduced drug efficacy or adverse drug effects 
especially in the elderly [6]. This is a result of declining 
organ function and multiple comorbid conditions that 
occurs with ageing. Furthermore, the prevalence of 
DM is disproportionately higher in the older popula-
tion because of increasing life expectancy especially 
in developing countries and this emphasises the need 
to address drug use patterns among individuals with 
diabetes. Increased mortality in hospitalised elderly 
patients has been associated with drug reactions [7]. 
Therefore, the use of appropriate drug therapy is im-
perative in diabetic care. 
Evidence-based guidelines have been developed to 
optimize treatment outcome and improve the quality 
of care among patients with DM. These guidelines 
provide recommendations for managing hyperglycae-
mia as well as the management of comorbidities and 
complications. Guidelines used in DM care include 
publications from the International Diabetes Federa-
tion (IDF), the American Diabetes Association (ADA), 
the American Association of Clinical Endocrinologists 
(AACE) and the Diabetes Association of Nigeria (DAN) 
[2, 4, 5, 8]. Studies have shown gaps in implementing 
guidelines in the management of patients with chronic 
diseases [9, 10]. 
Most studies have evaluated the use of glucose-
lowering drugs among persons with DM, with little 
attention paid to the management of comorbid con-
ditions among this population. Poor management of 
comorbidities and inappropriate drug combinations 
may obliterate the gains from glycaemic control. 
Therefore, it is important to evaluate the presence and 
treatment of comorbidities to improve clinical outcome 
in Diabetic care. This study investigated comorbidities 
and assessed the pattern of drug use concerning the 
presence of comorbid disorders in out-patient Type 2 
diabetic patients. 
Material and methods 
Study site
The study was conducted at the diabetes out-
patient clinic of the Department of Medicine, Lagos 
University Teaching Hospital (LUTH). 
Study design 
This was a cross-sectional study carried out among 
patients with type 2 DM for three months after obtain-
ing approval from the LUTH Health Research Ethics 
committee. A total of 216 patients who consented 
were included in the study. 
Inclusion criteria were men and women aged 18 
years and above with a diagnosis of type 2 diabetes 
mellitus (T2DM). Exclusion criteria are Type 1 diabetic 
and gestational diabetes. Questionnaires were admin-
istered by Medical House officers, who were blinded 
to the aims of the study. Patients were interviewed 
using a standard questionnaire and case notes were 
used to corroborate medications orders. Data was 
collected for demographic details (names, age, and 
sex of patients), diagnosis and comorbidities. The 
comorbidities assessed in this study include hyperten-
sion, dyslipidaemia, obesity, diabetes mellitus foot 
syndrome (DMFS), chronic kidney disease (CKD) and 
stroke. These comorbidities were ascertained based on 
patients’ report or a diagnosis of the specific comorbid-
ity in the case note. The prescribed drug, including the 
branded and generic name of all drugs used by patients 
(both prescription and non-prescription drugs), dose, 
dose frequency and route of administration were also 
recorded. Data were analysed using IBM SPSS version 
-18. Data were presented as frequencies, percentages, 
mean and standard deviation. 
Results
A total of 216 patients between the ages of 34 to 
89 years were recruited for the study. The duration of 
DM ranged from 1-46 years. At least one comorbidity 
was present in 99.54% of the population. Other demo-
graphic and comorbidity patterns are shown in Table 1.
Patterns of drug use 
The number of pills consumed per patient was 
from 1 to10 with a mean of 4.78 ± 1.73 (Fig.1). The 
majority (57.4%) were on 5 pills or more. A fixed-dose 
combination was used in 37 (17.1%) of the patients. 
Drugs commonly used are represented in figure 2 
below. Antidiabetic was used by 215 out of 216 diabetic 
patients, one patient was on dietary therapy. A total 
of 167 (77.31%) patients were on antihypertensive 
drugs against 153(70.8%) patients who reported hy-
pertension. Statins were utilized in 116 (53.7%) of the 
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participants whereas a total of 106 (49.1%) patients 
reported dyslipidaemia.
 Other drugs such as antacids, sildenafil, antiviral 
drugs, proton pump inhibitors, tamsulosin, antifungal, 
steroids and antiandrogen were used in less than 14%. 
Analgesics include tramadol, didydrocodeine and di-
clofenac, celecoxib. This is shown in figure 1.
Sulphonylureas (SU) used were long-acting gliben-
clamide, and glimepiride and short-acting gliclazide. 
Dipeptidyl peptidase-4 (DPP4) inhibitors included vilda-
gliptin, sitagliptin, linagliptin. Glucagon-like peptide-1 
(GLP-1) receptor agonists used was liraglutide while 
the only thiazolidinedione used was pioglitazone (See 
supplementary Table 1). 
An inappropriate combination of two drugs from 
the sulphonylurea class was observed in 3 patients 
and double RAS blockade was also observed in about 
13 (5%) patients (see supplementary Tables 1 and 2).
Discussion 
The study represented a population of type 2 dia-
betes mellitus in a tertiary health centre, the majority of 
the patients were 40 years and above and comorbidities 
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were common. Hypertension and dyslipidaemia were 
the most common comorbid conditions seen in the 
population. This study findings are similar to that of 
a multicentre study in sub-Saharan Africa which re-
ported high rates of comorbid conditions, hypertension 
was the most common which was reported in 71% of 
the population. This was followed by dyslipidaemia 
which was observed in 34% [11]. 
The study shows that the pill load among par-
ticipants was quite high, the majority (57.4%) of the 
participants were on 5 or more pills. This agrees with 
previous reports of a high drug burden among indi-
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viduals with T2DM [12–14]. The use of a high num-
ber of drugs has been associated with the presence 
of multi-morbidities among diabetes patients [15]. 
Multi-morbidities in DM may occur from the presence 
of other co-morbid cardiovascular risk factors and/or 
complications of DM. 
Generally, the concomitant use of several drugs in 
a patient which is termed polypharmacy is discouraged 
because of the increased risk of drug-related problems 
such as poor drug adherence, drug-drug interaction, 
drug-disease interaction, adverse effects, and increased 
cost of medications [16]. Most studies have used an 
arbitrary number of five drugs to define polypharmacy 
and have described the use of five or more drugs as 
irrational drug use. While the fear of polypharmacy is 
rational, it has been recommended that rational drug 
use should be judged based on the appropriateness of 
therapy rather than an absolute pill count [17]. 
Although the population studied are on polyphar-
macy, the drug use pattern appears to be appropriate 
for the majority of the patients in this study. The use of 
fewer than five drugs in this population may result in 
under-treatment because the majority of the patients 
had co-morbid diseases. 
The classes of drugs used in this study correlate 
with the patterns of co-morbidity seen in the popula-
tion (Fig. 1). The most commonly prescribed antidia-
betic drug in the study was metformin, which was used 
in two-thirds of the patients on monotherapy and in 
over 90% of the patients on polytherapy (Table 3). This 
is in line with the DAN, AACE/ACE and ADA guidelines 
that recommend the use of metformin as the first-line 
drug and as add-on therapy in those who need a sec-
ond antidiabetic drug in type 2 DM provided there is 
no contraindication to the use of metformin [4, 5, 8]. 
Metformin is effective in lowering HBA1C, weight and 
showed reduced CVS mortality compared to SU [18].
Other studies have also reported a preference for 
metformin as a first-line drug and also used frequently 
in combination therapy [19]. The use of DPP4I and 
alpha-glucosidase inhibitors as preferred first-line drugs 
have been documented in other regions for instance a 
study reported the use of alpha-glucosidase inhibitors 
in Beijing, China [20].
SUs were the second most prescribed drugs either 
in monotherapy or in combination with other drugs. 
This pattern has been described in other studies in 
Nigeria [21]. The most used SU in this study was glime-
piride with a relatively shorter half-life compared to 
glibenclamide. This conflicts with previous reports of 
a high uptake of glibenclamide which has a long half-
life [22]. SU with shorter half-lives are associated with 
a lower incidence of hypoglycaemia and are therefore 
preferred especially in the elderly who are more prone 
to hypoglycaemia. 
Other drug classes used among participants in 
this study include insulin analogues in 25%, DPP4I in 
21.8%, GLP-1 agonist in 0.5%, and thiazolidinedione 
in 0.5%. ADA guidelines recommend the early intro-
duction of insulin in patients with glycated HB above 
Table 2. Antidiabetic drug use among study participants
Drug Class n %
Biguanide (Metformin) 183 84.7
Sulphonylurea 113 52.3
 Glibenclamide 8 3.6
 Glimepiride 70 31.8
 Gliclazide 35 15.9
Insulin analogues 54 25
DPP4I 47 21.8
Thiazolidinediones 7 3.2
GLP-1 receptor analogue 2 0.9





DPP4I: dipeptidyl peptidase-4 inhibitors; SU: sulphonylureas; GLP: gluca-
gon-like peptide-1 (GLP-1) receptor agonists
Table 3. Antihypertensive use pattern among participants













CCB: calcium channel blockers; ACEI: angiotensin-converting enzyme 
inhibitors; ARB: angiotensin receptor blockers; BB: beta-blockers; ALPHA 
AGO: and centrally acting alpha agonists. Two diuretics include combi-
nations of indapamide + frusemide, hydrochlorthiazide + frusemide, 
spironolactone + torsemide and hydrochlorthiazide + spironolactone
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10% to reduce cardiovascular morbidity [4] AACE on 
the other hand recommended the addition of insulin 
when HbA1c is above 9% with symptoms [5]. The high 
rate of insulin use observed in this study may reflect 
higher baseline HBA1c or more advanced B-islet cell 
failure in the population. An increasing trend towards 
the use of DPP4I was also observed and may be due to 
its lower risk of hypoglycaemia and weight naïve effect 
compared to SU [21, 22]. 
Overall, antidiabetic drug use in this population 
complies with available guidelines, although the pre-
scription was limited to four classes of antidiabetic 
drugs. This may be related to tolerability, cost, availabil-
ity, and physician’s preference. Consideration for drugs 
classes like SGLT is important because of its benefit in 
patients with heart failure [4]. 
Antihypertensive drugs were used in 79.2 % of the 
population. This is disproportionately higher compared 
to the number who had hypertension. The higher 
rates may be attributed to the use of these drugs in 
other conditions, for example, ACEI or ARB are used 
in the management of proteinuria and beta-blockers 
in arrhythmias. Drugs used in monotherapy include 
calcium channel blockers (CCB), angiotensin-converting 
enzyme inhibitors (ACEI), angiotensin receptor blockers 
(ARB), diuretics and beta-blockers (BB). The use of CCB 
and thiazide diuretics as initial monotherapy follows 
the JNC 8 guideline which recommends the use of 
CCB and thiazide diuretics as first-line agents in black 
diabetic patients with co-morbid hypertension. This is 
because these classes of drugs have been associated 
with a more favourable cardiovascular outcome when 
compared to other classes of hypertensive drugs among 
blacks with DM [22]. Other guidelines have however 
recommended the use of ACEI or ARB as the preferred 
first-line in diabetics because of the protective effect 
on nephropathy and retinopathy [4, 5, 8]. A large pro-
portion of the participants are on either ACEI or ARB. 
Further comparative study on antihypertensive drugs is 
needed to provide robust evidence guiding the use of 
the first-line antihypertensive drug in blacks with DM.
An inappropriate combination of antihypertensive 
was observed in the participants and was associated 
with polypills. About 6% were on double RAS block-
ade. Initially, dual angiotensin blockade was advocated 
because the combination was shown to improve pro-
teinuria compared to a single agent from either class 
but recent evidence from randomised controlled trials 
showed higher risks of adverse effects like hyperkalae-
mia and declining renal function [24, 25]. As a result, 
the use of double RAS blockade in hypertension is no 
longer recommended [24]. A regular review of the 
medication is important to correct such practices even 
though many of these patients attend multiple clinics 
(nephrology, cardiology, and neurology) due to their 
co-morbid states. 
Statins are indicated for the treatment of dys-
lipidaemia and the prevention of macrovascular 
complications in patients with DM [4, 5, 8]. The ADA 
recommends the use of statin in all patients between 
40 - 75 years irrespective of CVS risk and levels of cho-
lesterol whereas statin use is recommended in the other 
guidelines based on risk stratification and cholesterol 
goals [5, 8]. There is a uniform consensus on the use 
of high-intensity statins for secondary prevention of 
atherosclerotic cardiovascular disease (ASCVD). 
In this study, only 54.6% of the participants were 
on statin, of these only 6.5% were on a high-intensity 
statin. This appears low considering that 49.1% had 
dyslipidaemia, 7.9% had a stroke and 12.5% had dia-
betes mellitus foot syndrome. DMFS may also suggest 
ASCVD because the condition occurs secondary to 
atherosclerotic peripheral vascular disease, peripheral 
neuropathy and infections. Presented findings sug-
gest that statins were prescribed in patients who had 
dyslipidaemia and ASCVD. Comparing with the ADA 
guideline, statin uptake is low since more than 95% of 
the population were 40 years and above. Low statin 
uptake has been reported in other studies, a study 
evaluating statin use among high-risk patients showed 
only about half of the patients 47.5% were on statin 
therapy [26]. 
Antiplatelet therapy using aspirin at a dose of 
75–162 mg/day is recommended for the secondary 
prevention of ASCVD in DM patients with a history of 
atherosclerotic cardiovascular disease [4]. Clopidogrel is 
recommended in patients with aspirin allergy [4]. There 
is no uniform consensus on the use of antiplatelet in 
primary ASCVD prevention. Antiplatelet drugs were 
used in 38% of the population and this is disproportion-
ally high compared to ASCVD prevalence. The number 
of patients on antiplatelet exceeds the number of 
Table 4. Statin and antiplatelet use among participants 
Drug n %
Statin use 118 54.6
High-Intensity Statin 14 6.5
Medium Intensity Statin 92 42.6




Statins used include atorvastatin, rosuvastatin and simvastatin
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participants with stroke and DMFS. This suggests that 
antiplatelet were used in both secondary and primary 
prevention of ASCVD. Risk stratification and discus-
sion with the patient is advised or essential if aspirin is 
considered for primary prevention [4].
Pregabalin and gabapentin were used in about a 
tenth of the population for the treatment of neuropath-
ic pain. The pattern of drug treatment largely complies 
with the ADA guideline which recommends the use 
of pregabalin, gabapentin and duloxetine for treat-
ing neuropathic pain in DM (ADA) [4]. A few patients 
were on nutritional supplements, supplements are not 
recommended unless there are specific indications [4].
 Although several studies have been carried out on 
drug use in diabetes, most of these only documented 
the use of antidiabetic or antihypertensive drugs, to 
the best of the authors’ knowledge, this study is one of 
the few studies that investigated all drug classes used 
in DM patients. It has been identified that a high drug 
load was appropriate in the majority of the patients.
Conclusion 
This study reported comorbidities and drug use 
pattern among diabetic patients and a tendency to use 
a large number of drugs which is appropriate because 
of the presence of co-morbid conditions. It also identi-
fied inappropriate drug combination patterns. There is 
a need to continue regular review of medications to 
optimize patient care. 
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